New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
18:27 EDTGWPH, SUNE, ADBE, ECYT, FLXN, ZBRA, LZB, MCRSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Adobe (ADBE), up 9% after reporting better than expected quarterly results. ALSO HIGHER: MICROS Systems (MCRS), up 1.8%... Flexion Therapeutics (FLXN), up 1.32% after announcing positive topline results from its Phase 2a pharmacokinetic trial... Sunedison (SUNE), up 1.35%. DOWN AFTER EARNINGS: La-Z-Boy (LZB), down 10.23% after reporting fourth quarter revenue below expectations. ALSO LOWER: Endocyte (ECYT), down 18.13% after announcing that Merck (MRK) will no longer pursue development of vintafolide... GW Pharmaceuticals (GWPH), down 5.25%... Zebra Technologies (ZBRA), down 4.6%.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 31, 2015
07:53 EDTZBRAZebra Technologies upgraded at Wells Fargo
Subscribe for More Information
07:51 EDTZBRAZebra Technologies upgraded on core business strength at Wells Fargo
Subscribe for More Information
07:08 EDTGWPHGW Pharmaceuticals initiates first Phase 3 pivotal trial for Epidiolex
GW Pharmaceuticals announces it has initiated the Phase 3 part of a Phase 2/3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW anticipates that top-line data from this trial will be available around the end of 2015.
06:04 EDTSUNESunEdison implied volatility of 44 at lower end of index mean range
Subscribe for More Information
06:04 EDTZBRAZebra Technologies upgraded to Outperform from Market Perform at Wells Fargo
March 30, 2015
17:44 EDTFLXNFlexion initiated with a Buy at MLV & Co.
Subscribe for More Information
07:21 EDTECYTSociety of Gynecologic Oncology to hold annual meeting
46th Annual Meeting of SGO is being held in Chicago on March 28-March 31.
March 26, 2015
08:30 EDTGWPHGW Pharmaceuticals risk/reward favorable into data, says Leerink
Leerink says the risk/reward on shares of GW Pharmaceuticals is favorable into the Epidiolex update at AAN on April 22 despite the 34% rally since the last update in October. The firm notes its price target of $102 assumes a 66% probability-of-success for Epidiolex in Dravet/Lennox Gastaut. Changing the probabilities to 100% yields a target of $182, Leerink notes. It reiterates an Outperform rating on GW.
07:33 EDTSUNESunEdison partners with City of Long Beach to provide 2.5MW of solar power
Subscribe for More Information
March 25, 2015
08:10 EDTADBETarena signs strategic partnership agreement with Adobe Creative University
Subscribe for More Information
07:31 EDTSUNESunEdison purchases 1K energy storage systems from Imergy
SunEdison announced that it plans to purchase up to 1,000 vanadium flow batteries from Imergy Power Systems. The vanadium flow batteries will be used to store solar-generated electricity for SunEdison's rural electrification and solar powered minigrid projects in India. SunEdison will also increase its equity investment in Imergy. This aims to strengthen the supply relationship between the two companies as SunEdison begins deployment of its extensive rural electrification program in India.
March 24, 2015
13:57 EDTADBEMicrosoft partnering with Adobe on Project Spartan
Subscribe for More Information
March 23, 2015
16:11 EDTFLXNFlexion provides outlook on 2015
Michael Clayman, M.D., President and CEO of Flexion, stated, "For Flexion Therapeutics, 2014 was a transformational year. We completed two public stock offerings that place the company in a strong position to execute on its business plan. To that end, the Flexion team has advanced FX006 into two pivotal clinical trials that we expect will form the basis for a regulatory submission for a product that has the potential to make a meaningful and durable difference for the many patients suffering from OA knee pain. In addition, we strengthened our board of directors and management team." Dr. Clayman continued, "We expect 2015 to be another important year for the company as the readout from our first pivotal trial will happen later this year along with completion of enrollment in our Phase 3 trial. With positive data from both trials we look forward to the prospect of filing a New Drug Application thereafter." In 2015, the company expects to announce the results of pivotal Phase 2b trial in the fourth quarter and complete final, pivotal Phase 3 clinical trial enrollment for FX006.
11:22 EDTADBEOptions with decreasing implied volatility
Options with decreasing implied volatility: FOLD NKTR RUSL XONE GES CTRP WSM NLY ADBE ORCL
March 18, 2015
16:26 EDTADBEOn The Fly: Closing Wrap
Subscribe for More Information
10:21 EDTADBEHigh option volume stocks:
Subscribe for More Information
09:36 EDTADBEActive equity options trading on open
Subscribe for More Information
09:23 EDTADBEOn The Fly: Pre-market Movers
Subscribe for More Information
08:32 EDTADBEAdobe should be bought on weakness, says Pacific Crest
Subscribe for More Information
07:32 EDTSUNESunEdison to provide Georgetown, Texas, with 150 MW of solar power
SunEdison (SUNE) will construct new solar plants in West Texas to supply the City of Georgetown with 150 MW of solar power for 25-years. The SunEdison solar plants will be interconnected in 2016, and will provide over 9,500 gigawatt-hours of clean energy to Georgetown through 2041. Upon completion, SunEdison expects to offer this project for investment to TerraForm Power (TERP).
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use